Where Karuna Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Karuna Therapeutics (NASDAQ:KRTX) has received 8 analyst ratings in the last quarter, all of which are bullish or somewhat bullish. The average price target is $271.5, representing an upside from the current price of $203.71. This is a slight decrease from the previous average price target of $272.33. Analysts rate stocks to provide investment guidance, but their advice may be subject to error.
December 12, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karuna Therapeutics has received 8 positive analyst ratings with no neutral or negative ratings in the last quarter. The average price target suggests a significant upside potential from the current stock price.
The unanimous bullish sentiment from analysts, coupled with a price target significantly higher than the current stock price, is likely to instill confidence in investors and could lead to a short-term increase in the stock price. However, the slight decrease in the average price target from the previous quarter indicates a need for caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100